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Abstract
Introduction: Selective digestive decontamination (SDD) appears to have a more compelling evidence base than
non-antimicrobial methods for the prevention of ventilator associated pneumonia (VAP). However, the striking
variability in ventilator associated pneumonia-incidence proportion (VAP-IP) among the SDD studies remains
unexplained and a postulated contextual effect remains untested for.
Methods: Nine reviews were used to source 45 observational (benchmark) groups and 137 component (control
and intervention) groups of studies of SDD and studies of three non-antimicrobial methods of VAP prevention. The
logit VAP-IP data were summarized by meta-analysis using random effects methods and the associated
heterogeneity (tau
2) was measured. As group level predictors of logit VAP-IP, the mode of VAP diagnosis,
proportion of trauma admissions, the proportion receiving prolonged ventilation and the intervention method
under study were examined in meta-regression models containing the benchmark groups together with either the
control (models 1 to 3) or intervention (models 4 to 6) groups of the prevention studies.
Results: The VAP-IP benchmark derived here is 22.1% (95% confidence interval; 95% CI; 19.2 to 25.5; tau
2 0.34)
whereas the mean VAP-IP of control groups from studies of SDD and of non-antimicrobial methods, is 35.7 (29.7 to
41.8; tau
2 0.63) versus 20.4 (17.2 to 24.0; tau
2 0.41), respectively (P < 0.001). The disparity between the benchmark
groups and the control groups of the SDD studies, which was most apparent for the highest quality studies, could
not be explained in the meta-regression models after adjusting for various group level factors. The mean VAP-IP
(95% CI) of intervention groups is 16.0 (12.6 to 20.3; tau
2 0.59) and 17.1 (14.2 to 20.3; tau
2 0.35) for SDD studies
versus studies of non-antimicrobial methods, respectively.
Conclusions: The VAP-IP among the intervention groups within the SDD evidence base is less variable and more
similar to the benchmark than among the control groups. These paradoxical observations cannot readily be
explained. The interpretation of the SDD evidence base cannot proceed without further consideration of this
contextual effect.
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Colonization and infection with bacteria occurs com-
monly in patients receiving mechanical ventilation (MV)
[1-5]. The use of selective digestive decontamination
(SDD) is an approach to prevent colonization and pneu-
monia in this patient group [6]. Systematic reviews
of more than 30 controlled studies of SDD provide
compelling evidence of reductions in VAP of >50% [6]
versus marginally significant reductions of <20% with
non-antibiotic methods of prevention such as those
based on the management of gastric pH [7], tracheal
suction [8], or humidification [9].
That SDD could create a contextual effect in the
intensive care unit through cross colonization between
patients of concurrent control and study groups was
postulated in the original 1984 study [10] and others
[11], which were intentionally non-concurrent in design.
This postulate remains untested. Moreover, the VAP-IP
of control groups of SDD studies is highly variable, par-
ticularly among SDD studies with a concurrent design
[12]. To account for this variability and to test the origi-
nal postulate would require an external benchmark of
VAP-IP.
Four recent factors enable a benchmarking of the
VAP-IP among the component groups of the SDD evi-
dence base. First, five reviews [1-5] have independently
estimated the expected VAP-IP range for observational
groups and enable the derivation of a benchmark. Sec-
ond, the key studies in the evidence base for SDD and
for comparison, three non-antibiotic methods of VAP
prevention, are identified in four large systematic
reviews [6-9]. Third, various group level factors, which
may be explanatory toward the VAP incidence, are iden-
tified in all of the studies. Finally, heterogeneity among
study results can now be measured and incorporated in
the derivation of a prediction range using recently devel-
oped random effects methods of meta-analysis and dis-
played using a caterpillar plot [13,14].
Materials and methods
Overview
There are four objectives here: First, to derive a VAP-IP
benchmark and prediction range derived from observa-
tional (benchmark) groups. Second, to summarize VAP-
IP separately for the control and intervention groups
from studies of two broad approaches to VAP preven-
tion that have been included in systematic reviews; stu-
dies of SDD versus studies of non-anti-microbial
methods of VAP prevention. Third, to assess the disper-
sion among the group specific VAP-IP of control groups
and intervention groups versus the VAP-IP benchmark
using caterpillar plots. Finally, to assess the impact of
group level factors as possible explanatory variables
toward the group specific VAP-IP in meta-regression
models that include both the benchmark and the pre-
vention study groups.
Study selection and component group designations
This analysis is limited to component groups from stu-
dies of patients receiving mechanical ventilation as
abstracted in nine published reviews (four non-systematic
and five systematic) of VAP incidence and specific VAP
prevention methods [1-9]. The unit of analysis here is the
component patient group, whether observational (bench-
mark) [1-5], or control or intervention groups from stu-
dies of various methods of VAP prevention [6-9].
The inclusion criterion for this analysis was a study of
adult patients receiving prolonged mechanical ventila-
tion in intensive care units (ICUs) for which VAP-IP
and denominator data had been abstracted in one of the
nine reviews [1-9]. The exclusion criteria as specified in
the Cochrane review [6] are applied to achieve harmoni-
zation across the studies obtained from all nine reviews.
That is; studies based on specific pre-selected types of
patients (patients undergoing elective esophageal resec-
tion, cardiac or gastric surgery, liver transplant or suffer-
ing from acute liver failure), studies of non-ICU
populations, populations for which the proportion
receiving MV for >24 hours was <50% and studies for
which VAP-IP data were not available. Also, studies of
pediatric populations, and studies published before 1984
do not appear among the studies abstracted in the
review of Liberati et al. [6] and these study types are
also excluded.
Categories of benchmark and component groups
The benchmark groups are those groups of observa-
tional studies as abstracted in one of five reviews of
VAP incidence [1-5]. Any intervention study abstracted
i no n eo ft h e s ef i v er e v i e w so fV A P - I Pi n c i d e n c ew a s
not used in the derivation of the benchmark.
The component groups of studies of non-antimicro-
bial methods of VAP prevention are as abstracted in
one of three systematic reviews of various methods of
gastric acid suppression [7], open versus closed methods
of tracheal suction [8], or passive versus active humidifi-
cation [9] as methods of VAP prevention. In the gastric
acid studies, the interventions studied were those that
might suppress gastric acid (for example, ranitidine or
antacid treatment) versus interventions that did not (for
example, no treatment or sucralfate) [7]. The designa-
tion of control and intervention groups were as indi-
cated in the systematic reviews of open (control) versus
closed (intervention) methods of tracheal suction [8]
and passive (HH, control) versus active (HME, interven-
tion) humidification [9]. The component groups from
the studies of SDD are as abstracted in the Cochrane
review [6].
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The primary outcome is the VAP-IP, which is the inci-
dence of ventilator associated pneumonia per 100
patients. The VAP-IP and its denominator were taken
for all component groups as abstracted in the review
documents in which they appeared.
Additional information abstracted directly from the
original publication was whether the mode of VAP diag-
nosis required bronchoscopic sampling versus tracheal
sampling methods, whether <90% of patients received at
least 24 hours of mechanical ventilation, and the pro-
portion of patients admitted to the ICU for trauma. The
scoring of study quality was also abstracted from each
systematic review. However, each systematic review used
different quality scoring systems and scoring was not
used in the non-systematic reviews. The indicator of
highest study quality in this analysis was whether the
study received a majority score in the source systematic
review. Data were extrapolated from tables and
figures if not available in the text. Care was taken to
stratify patient groups appearing across more than one
publication.
Caterpillar plots
A caterpillar plot is a forest plot-like display of group
specific odds and 95% confidence intervals with the stu-
dies listed in rank order of increasing event rate. This
display reveals both the overall symmetry of the indivi-
dual group results and their deviation from the overall
mean. This display shows the impact of group size with
the larger groups, having greater precision, expected to
deviate less from the summary or benchmark.
Statistical methods
The VAP-IP data were converted to logits for analysis as
follows; if D represents the denominator, N represents
the numerator, and R represents the proportion (N/D)
of the VAP-IP, the logit(VAP-IP) is log(N/(D-N)) and its
variance is 1/(D*R*(1-R)) [15,16]. This variance formula
was used to calculate the group specific 95% confidence
intervals. Using these calculated logits and logit var-
iances, the metan command [17] in STATA (release
11.0, STATA Corp., College Station, TX, USA) gener-
ates summary logits by a random effects method
together with the standard errors (SE) and tau
2,w h i c h
are measures of within and between group variances,
respectively, and the associated 95% CI’s. The metan
command also generates the caterpillar plots of the
group specific logits and 95% CI’s.
The VAP-IP benchmark was derived as the mean logit
VAP-IP and 95% confidence interval derived together
with a 95% prediction interval. The later is calculated
using the metan command as mean ± 1.96 * (SE
2 +
tau
2)
0.5 [17]. In each of the caterpillar plots, both the
overall VAP-IP mean derived from the groups in the
plot and the 95% prediction interval derived from VAP-
IP benchmark range are displayed.
To test the stability of the benchmark, five replicate
derivations of the VAP-IP benchmark were derived
using the VAP-IP data abstracted from the four non-
systematic and one systematic reviews individually [1-5].
Meta-regression
The calculated logits and logit variances were used with
the metareg command [18] in STATA (release 11.0,
STATA Corp.) to perform meta-regression models that
incorporate group level factors as predictors. There are six
meta-regression models of logit VAP-IP including the
benchmark groups with either the control (models 1 to 3)
or the intervention (models 4 to 6) groups of the prevention
studies. Models 1 and 4 include group membership (bench-
mark, SDD study or non-antimicrobial method study), as
the only predictors. Models 2 and 5 include three additional
group level properties as predictor variables; whether <90%
of patients in the group received >24 hours of MV, whether
the mode of diagnosisof VAP required bronchoscopicsam-
pling and the proportion of trauma admissions to the ICU.
Models 3 and 6 replicate models 2 and 5 but are limited
to those studies that had received majority quality scores
in the source systematic reviews. Regression coefficients
were compared using the lincom (linear combination) post-
estimation command inSTATA.
Sensitivity analysis
Meta-regressions models 2 and 4 were repeated after
exclusion of studies for which the proportion of patients
receiving >24 hours of mechanical ventilation was <90%
or unknown. Also, meta-regressions models 3 and 6
were repeated with component groups from 19 studies
of SDD that had received a quality score of one out of
two included.
Results
There were 45 observational benchmark groups (Addi-
tional file 1) [19-63] and 137 component groups (Addi-
tional files 2 and 3) [64-131] derived from nine reviews
[1-9]. The characteristics of the studies and the groups
are summarized in Table 1. Most studies had been pub-
lished in the 1990’s. Compared to the benchmark
groups, the component groups of the studies of VAP
prevention methods differed in the following respects;
they had fewer patients per group (P = 0.001), fewer
had bronchoscopic sampling performed for VAP diag-
nosis (P = 0.003) and admissions for trauma among
them were more frequent (P = 0.01). The studies of
non-antimicrobial methods more often attained majority
quality scores than did studies of SDD in the respective
systematic reviews (P = 0.006).
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tional (benchmark) groups is 22.1% with a 95% confi-
dence interval of 19.0% to 25.5%, and with a 95%
prediction interval of 8.6% to 47.3% (Figure 1). The five
replicate estimates of the benchmark using the abstracted
VAP-IP data from the observational (benchmark) groups
abstracted in each of the four non-systematic and one
systematic reviews were each within five percentage
points of the benchmark derived using the abstracted
VAP-IP data from all 45 observational (benchmark)
groups (Table 2). Among the benchmark groups, there
was no significant trend in VAP-IP versus publication
year (data not shown, P = 0.47). A summary VAP-IP
derived from benchmark groups originating from
European centres and non-European centres were each
within two percentage points of the benchmark (Table 2).
T h eg r o u ps p e c i f i ca n ds u m m a r yV A P - I P ’sf o rt h e
component groups of the prevention studies are dis-
played in Figures 2, 3, 4, 5 and the summary VAP-IPs
are tabulated in Table 3. The I
2 associated with the
summary estimates ranged between 74% and 93%. The
distribution of the group specific VAP-IPs of the control
groups of the SDD studies differs in five ways versus the
distribution of the group specific VAP-IPs among the
control groups of the studies of non-antibiotic methods;
the mean and tau
2 are 50% higher (Table 3) and the
interquartile range (IQR) (Table 1) and confidence inter-
vals (Table 3) are both 50% wider. Moreover, the
median VAP-IP (Table 1) of the control groups of the
SDD studies is more than five percentage points higher
than the mean (Table 3), a finding which indicates a
positive skew.
Table 1 Characteristics of studies and component groups
Studies and component groups
Observational (Benchmark) Non-antimicrobial SDD
Studies
Originating review [ref] [1 to 5]
a [7 to 9]
b [6]
c
Number of studies
d, e 45 35 33
Bronchoscopic sampling
f 23 5 8
Publication year (IQR)
g 1990 to 2000 1994 to 2000 1991 to 1997
European
h, i 28 19 30
Majority quality score
j, k NA 16 4
MV for > 24 hours for <90%
l 52 4
Component groups
Numbers of patients per group; median (IQR)
m, n 264; 83 to 567 54; 29 to 92 57; 33 to 130
Days of ventilation; median (IQR)
o 10.8; 8.0 to 12.8 8.9; 6.7 to 13.4 10.5; 9.0 to 15.0
% trauma patients; median (IQR)
p 12; 2 to 35 15; 10 to 59 34; 18 to 78
VAP - IP; median IQR (n)
Observational (benchmark) 22.0; 15 to 30.8 (45) NA NA
Control 17.5; 12.5 to 28.9 (35) 42; 21.6 to 51(33)
Intervention 15.4; 9.1 to 22.7 (35) 13.3; 7.1 to 24.4 (34)
n, number; NA, not available; IQR, inter-quartile range; SDD, Selective Digestive Decontamination; VAP-IP, ventilator associated pneumonia incidence proportion.
aThese data were sourced as follows; George, 1993 [1] (Table 1), Cook and Kollef, 1998 [2] (Table 1), Chastre and Fagon, [3] 2002 (Table 1), Bergmans and Bonten,
[4] 2004 (Table 22.5), Safdar et al., [5] 2005 (Table 1).
bThe following systematic reviews were the source for these studies; Messori et al., [7] 2000 (Tables 5-7), Subirana et al., [8] 2007 (Table 7), and Siempos et al.,[ 9 ]
2007 (Table 2) were the sources for these studies.
cLiberati et al., [6] 2009 (Analysis 1.5, and 2.5) was the source for these studies.
dReasons for benchmark group exclusions; 9 studies of defined patient populations (pediatric, cardio-thoracic surgery, liver transplantation, ARDS), 12 studies with
<50% of patients receiving MV >24 hours, 6 studies published prior to 1983, or 6 intervention studies.
eReasons for VAP prevention study exclusions; 2 studies of defined patient populations (cardio-thoracic surgery, liver transplantation), or VAP-IP data not available
(12 studies).
fComparison of mode of diagnosis, chisquared test = 13.5, two degrees of freedom P = 0.001.
gData is inter-quartile range (IQR).
hOriginating from a member state of the European Union as at 2010 or Switzerland or Norway.
iComparison of European origin, benchmark versus prevention studies, chisquared test = 1.4, one degree of freedom P = 0.24.
jA majority quality score as assessed in the originating systematic reviews which had been scored out of a possible 10 [7], 4 [8], 5 [9] and 2 [6] criteria.
kComparison of high quality score, chisquared test = 7.43, one degree of freedom P = 0.006.
lNumber of studies for which the proportion of patients ventilated for >24 hours was <90% or not stated.
mData is median and inter-quartile range (IQR).
nComparison of group sizes, chisquared test = 34.7, two degrees of freedom P = 0.0001.
oComparison of days of ventilation, chisquared test = 1.4, two degrees of freedom P = 0.49.
pComparison of percent of trauma patients, chisquared test = 7.5, two degrees of freedom P = 0.02.
Hurley Critical Care 2011, 15:R7
http://ccforum.com/content/15/1/R7
Page 4 of 17The differences in distributions of VAP-IP among the
component groups of the prevention studies are also
apparent in the caterpillar plots (Figures 2, 3, 4, 5) in
that 11 of the 33 control groups of the SDD studies ver-
sus only 3 of the 35 control groups of the non-antibiotic
studies have group specific VAP-IP’s which are above
the benchmark 95% prediction interval. Four of the
control groups with VAP-IP within the benchmark pre-
diction range were control groups from SDD studies
that had a duplex design; that is, all control group
patients routinely received systemic antibiotics.
The disparities in summary VAP-IP among the com-
ponent groups of the prevention studies versus the
benchmark remained apparent in analyses limited to the
Figure 1 Caterpillar plot: observational (benchmark) groups and derived benchmark. Caterpillar plot of the group specific (small
diamonds) VAP-IP and 95% CI of observational benchmark groups together with the summary VAP-IP (dotted green vertical line), 95% CI (large
open diamond) and 95% prediction interval (solid green horizontal line). Note that the x axis is a logit scale. The VAP-IP data is as abstracted in
four non-systematic and one systematic review [1-5].
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the control groups of highest quality SDD studies were
22 percentage points higher than the benchmark. By
contrast, for all other component groups the summary
VAP-IP’s were within seven percentage points of the
benchmark whether derived from the highest quality
studies or all studies.
Meta-regression models
Three meta-regression models were performed as
described in the methods to evaluate several group level
properties as predictors of the group specific logit VAP-
IP’s of the control (Table 4) and intervention (Table 5)
groups versus the benchmark groups.
For the control groups versus the benchmark groups
(Table 4; meta-regression models 1 to 3), membership
of a control group of an SDD study was a consistently
positive predictor. For the intervention groups versus
the benchmark groups (Table 5; meta-regression models
4 to 6), membership of an intervention group of an
SDD study was a negative predictor of logit VAP-IP but
not consistently significant.
In comparing these factors in the meta-regression
models, membership of a control group of an SDD
study differed significantly versus membership of a
control group of a non-antibiotic study in model 1 (P <
0.001), model 2 (P < 0.001) and model 3 (P = 0.003). By
contrast, membership of an intervention group of an
SDD study did not differ significantly versus member-
ship of an intervention groupo fan o n - a n t i b i o t i cs t u d y
as a predictor in model 4 (P = 0.7), model 5 (P = 0.6) or
model 6 (P = 0.3).
Meta-regressions models 2 and 4 were repeated after
exclusion of studies for which the proportion of patients
receiving >24 hours of mechanical ventilation was <90%
or unknown. Also, meta-regressions models 3 and 6
were repeated with component groups from 19 studies
of SDD that had received a quality score of one out of
two included. With both of these re-analyses, the find-
ings were replicated (data not shown).
Discussion
The present analysis has identified unexplained and
paradoxical discrepancies among the VAP-IP of control
groups and the intervention groups of SDD studies ver-
sus the benchmark and versus groups of other studies
aggregated from reviews of other methods of VAP pre-
vention. There were several analytic and statistical issues
that needed to be addressed to execute this analysis.
The first analytic issue is the method of study selection.
The objective here was to evaluate the evidence base as
represented within systematic and other reviews. Hence a
new literature search was not undertaken but the analysis
was specifically limited to studies identified in nine pub-
lished reviews and to the use of those studies exclusively.
This narrowed focus allows scrutiny of the component
groups that form an entire evidence base [6-9]. The three
systematic reviews of non-antibiotic methods of VAP pre-
vention were chosen because they were the largest available.
The second analytic issue is the method of abstracting
VAP-IP data. The use of abstracted data from the
reviews rather than from the published studies main-
tains objectivity and facilitates independent verification
as all the data is readily identifiable in the reviews. Of
note, the method of VAP-IP abstraction for the SDD
review [6] was somewhat unique in that these authors
had contacted investigators of the original SDD studies
to obtain ‘intention to treat’ d a t a .H e n c e ,t h eS D Dd a t a
includes missing data for 25 of the 36 SDD studies with
published data used for the remaining 11 studies. How-
ever, applying the benchmark 95% prediction range to
the VAP-IP data as published in all 33 studies yields
similar discrepancies [12].
The third analytic issue is that the VAP-IP is propor-
tion data arising from groups with varying denomina-
tors. Transformation to logits and weighting by the
inverse variance as a method of adjusting for variable
study size are standard methods for analysis of propor-
tion data [15,16].
Table 2 Sources and replicate estimates of VAP-IP
benchmark range
VAP-IP range estimates (%)
Source review, Year Original
a Re-analysis
b
N Mean; 95% CI N
c
George, 1993 [1]
d 8 to 54 23 23.7; 18.1 to 30.4 11
Cook and Kollef, 1998 [2]
d 13 to 38 8 21.4; 17.5 to 25.7 8
Chastre and Fagon, 2002 [3]
d 8 to 28 10 17.2; 13.4 to 22.1 10
Bergmans and Bonten,
2004 [4]
d
8.6 to 65 15 20.6; 16.1 to 26.1 14
Safdar, et al., 2005 [5]
e 7 to 12.5 28 21.1; 17.9 to 24.4 25
All five reviews [1-5] 22.1; 19.2 to 25.5
f 45
European benchmark
groups [1-5]
21.2; 18.1 to 24.6 28
Non- European benchmark
groups [1-5]
23.9; 19.6 to 28.8 17
VAP-IP, Ventilator associated pneumonia incidence proportion, N, number of
groups.
a.The original VAP-IP range and numbers of abstracted studies (N) had been
derived in the source systematic review by the following methods; minimum-
maximum study VAP-IP values [1-3] or mean VAP-IP weighted by study size
[5] or unstated [4].
b. Re-analysis VAP-IP range derived by meta-analysis using the abstracted
VAP-IP data and numbers of eligible abstracted studies (N) from each
systematic review.
c. The number of eligible groups (N) from each systematic review included in
the re-analysis. Note, the column does not tally as some studies were
abstracted in more than one systematic review.
d. Non-systematic review.
e. Systematic review.
f. This is the benchmark range.
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in the intervention under study. It should be noted that
profiling the component groups of the prevention stu-
dies against the benchmark is the objective of the analy-
sis here rather than estimating the summary effect size
for the interventions under study. In this regard, the
control groups are of particular interest. If there is no
contextual effect associated with the study of SDD
within an ICU, it would be expected that the control
groups of concurrent design SDD studies would have
Figure 2 Caterpillar plot: control groups of studies of non-antimicrobial methods of VAP prevention. Caterpillar plot of the group
specific (small diamonds) and summary (broken vertical line) VAP-IP and 95% CI (large open diamond) of control groups of studies of non-
antimicrobial methods of VAP prevention. The VAP-IP data is as abstracted in three systematic reviews [7-9]. For comparison, the VAP-IP
benchmark (solid green vertical line) and prediction interval (solid green horizontal line) derived from the benchmark groups from Figure 1 is
also shown. Note that the x axis is a logit scale.
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benchmark and also to the VAP-IP’s of control groups
of studies of other prevention methods.
The fifth issue is that the quality scores of the studies as
rated in each systematic review varied. Also, different
scales of study quality were used in each of the systematic
reviews. As a consequence, a majority quality score as
rated by each systematic review was used as a unified
rating of highest study quality. Paradoxically, the dispari-
ties in VAP-IP noted here are most apparent in compari-
sons limited to the highest quality studies.
The sixth issue is the heterogeneity (over-dispersion) in
event rates arising from different patient populations in
different centres. This is apparent in all of the summary
ranges here in that all have I
2 values above 75% which
indicate high levels of heterogeneity [132]. Heterogeneity
Figure 3 Caterpillar plot: intervention groups of studies of non-antimicrobial methods of VAP prevention. Caterpillar plot of the group
specific (small diamonds) and summary (broken vertical line) VAP-IP and 95% CI (large open diamond) of intervention groups of studies of non-
antimicrobial methods of VAP prevention. The VAP-IP data is as abstracted in three systematic reviews [7-9]. For comparison, the VAP-IP
benchmark (solid green vertical line) and prediction interval (solid green horizontal line) derived from the benchmark groups from Figure 1 is
also shown. Note that the x axis is a logit scale.
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the performance of hospitals and surgeons toward the
identification of individual outlier performers. Adjusting
for patient risk is an important consideration in profiling,
but this is problematic when comparing multiple centres
[133]. It should be noted that identification of individual
outlier performers is not an objective of this analysis
but rather the estimation of the overall VAP-IP range
among the component groups that comprise an entire
evidence base and the identification of group level
Figure 4 Caterpillar plot: control groups of SDD studies. Caterpillar plot of the group specific (small diamonds) and summary (broken
vertical line) VAP-IP and 95% CI (large open diamond) of control groups of SDD studies. Four control groups from duplex studies that is, all
control group patients routinely received systemic antibiotics, are indicated by an asterix next to the author name and NC indicates non-
concurrent. The VAP-IP data is as abstracted in Liberati et al. [6]. For comparison, the VAP-IP benchmark (solid green vertical line) and prediction
interval (solid green horizontal line) derived from the benchmark groups from Figure 1 is also shown. Note that the x axis is a logit scale.
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VAP-IP.
A more recent development in relation to managing
heterogeneity is to measure it using random effects meth-
ods [13,14,132]. With random effects methods, both the
variance arising from between groups (heterogeneity,
tau
2) versus that from within groups (sampling, SE) are
estimated and both types of variability are incorporated
in the calculation of the 95% prediction intervals with as
a result, more conservative (wider) prediction intervals
than would be derived using traditional fixed effects
methods which do not take heterogeneity into account.
Figure 5 Caterpillar plot: intervention groups of SDD studies. Caterpillar plot of the group specific (small diamonds) and summary (broken
vertical line) VAP-IP and 95% CI (large open diamond) of intervention groups of SDD studies. The VAP-IP data is as abstracted in Liberati et al.
[6]. For comparison, the VAP-IP benchmark (solid green vertical line) and prediction interval (solid green horizontal line) derived from the
benchmark groups from Figure 1 is also shown. Note that the x axis is a logit scale.
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mens studied. The most common regimen used in the
studies included here was a topical combination of poly-
myxin, tobramycin and amphotericin together with, for
13 of the SDD intervention groups, a parenteral antibio-
tic [134]. Given the heterogeneity in the SDD treat-
ments, surprisingly the IQR (Table 1) was wider and the
tau
2 (Table 3) was higher for the control groups of the
SDD studies than for the corresponding intervention
groups and also versus the control and intervention
groups of studies of three different types of non-antibio-
tic prevention methods. These are paradoxical findings.
The seventh issue is observer bias and the lack of an
objective gold standard for VAP. In part this issue relates
to study design and the blinding of observers and adequate
concealment of group allocation, factors that have been
assessed as part of the study quality ratings used in each of
the systematic reviews. More particularly, lack of an
Table 3 Study quality and summary estimates of VAP-IP
Strata of groups All studies Highest quality studies
a
Mean; 95% CI N SE tau
2 Mean; 95% CI N SE tau
2
Observational (benchmark) groups 22.1; 19.2 to 25.5 45 0.09 0.34 22.1; 19.2 to 25.5 45 0.09 0.34
Studies of VAP prevention using non-antimicrobial methods
Control groups 20.4; 17.2 to 24.0 35 0.13 0.41 18.4; 14.9 to 22.3 16 0.16 0.24
Intervention groups 17.1; 14.2 to 20.3 35 0.13 0.35 15.3; 12.6 to 18.7 16 0.13 0.16
Studies of methods of VAP prevention using SDD
Control groups 35.7; 29.7 to 41.8 33 0.15 0.63 44.7; 31.1 to 59.3
b 4 0.39 0.52
Intervention groups 16.0; 12.6 to 20.3 34 0.16 0.59 18.5; 9.9 to 32.1
c 4 0.53 0.90
CI, confidence interval; N, number; SE, Standard error; SDD, Selective Digestive Decontamination; VAP, Ventilator associated pneumonia.
a. The study quality scoring was as defined in the source systematic reviews. The highest quality score is a majority quality score as assessed in the originating
systematic reviews which had been scored out of a possible 10 [7], 4 [8], 5 [9] and 2 [6] criteria. Benchmark groups had not been rated with a quality score in
the review sources and for this analysis are considered to be of equal quality.
b. Summary estimates derived for 24 control groups of SDD studies which had a high quality score (1 out of 2) was 34.8; 28.7 to 58.5 (se = 0.15, tau
2 = 0.43).
c. Summary estimates derived for 25 intervention groups of SDD studies which had a high quality score (1 out of 2) was 17.9; 13.8 to 23.1 (se = 0.18, tau
2 = 0.60).
Table 4 Meta-regression models 1-3: benchmark and control groups
Meta-regression analysis of logit VAP-IP
Factor Coefficient
a 95% confidence interval P
Simple model (model 1; all studies)
Benchmark groups (reference group) -1.26 -1.47 to -1.05 <0.001
Non-antimicrobial series -0.10 -0.44 to +0.24 0.56
SDD series +0.67 +0.34 to +1.00 <0.001
Full model (model 2; all studies)
Benchmark groups (reference group) -1.07 -1.37 to -0.77 <0.001
Non-antimicrobial series -0.38 -0.74 to -0.03 0.04
SDD series +0.48 +0.16 to +0.81 0.004
Mode of diagnosis
b -0.38 -0.68 to -0.08 0.01
Proportion trauma admissions
c +0.30 -0.10 to +0.70 0.14
<90% ventilated patients
d -0.41 -0.88 to +0.06 0.09
Full model (model 3; highest quality studies)
Benchmark groups (reference group) -0.98 -1.27 to -0.66 <0.001
Non-antimicrobial series -0.35 -0.75 to +0.06 0.09
SDD series +0.82 +0.14 to +1.50 0.019
Mode of diagnosis
b -0.38 -0.72 to -0.04 0.03
Proportion trauma admissions
c -0.13 -0.58 to +0.33 0.58
<90% ventilated patients
d -0.31 -0.83 to +0.22 0.24
SDD, Selective Digestive Decontamination; VAP-IP, Ventilator associated pneumonia incidence proportion.
a. Interpretation. The benchmark groups in each model form the reference group and the size of this coefficient equals the difference in logits from 0 (a logit
equal to 0 equates to a proportion of 50%; a logit equal to -1.26 equates to a proportion of 22.1%). The other coefficients in each model represent the additional
difference in logits for groups positive for that factor versus the reference group.
b. For diagnosis using bronchoscopic versus tracheal based sampling.
c. Per 100% of admissions being for trauma.
d. For studies for which <90% of patients received >24 hours of mechanical ventilation.
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VAP for which there are several definitions in use, with
those that require bronchoscopic based sampling being
possibly a more specific but less sensitive diagnostic stan-
dard [135].
Additional to this is that some of the studies included
patients who were not ventilated, which is problematic
for the diagnosis of VAP. Also, the proportion of
patients admitted for trauma, used here as a surrogate
for the patient mix, ranged between 0% and 100%
among the studies. These issues in VAP diagnosis have
been identified as group level factors in meta-regression
models 2, 3, 5 and 6.
Limitations of this analysis
There are several limitations of this analysis. The ran-
dom effects method of analysis presumes that the
groups in each summation are representative of a ‘ran-
dom’ selection of an undefinable super-population of
groups. The VAP-IP benchmark derived here may only
be representative of patient groups as found within sys-
tematic reviews.
Only nine reviews were used in this analysis and other
smaller reviews have not been included. However, other
reviews applicable to this patient group can be tested
against the 95% prediction range derived from the
benchmark groups here. For example, systematic reviews
of kinetic bed [136] therapy and topical chlohexidene
[137] as methods for the prevention of VAP had identi-
fied 10 and 7 studies respectively. Of the 17 studies
identified in these two systematic reviews, only two stu-
dies, one from each systematic review, had a control
group with a VAP-IP above 47.3%, the upper 95% limit
of the prediction range derived from the benchmark
groups here, whereas three had an intervention group
VAP-IP below the lower 95% limit of the prediction
range derived from the benchmark groups.
Also, studies of SDD which had a non-concurrent
design have not been included in the meta-regression.
This would help to test the postulated contextual effect
of SDD. Among the SDD studies included here, three
have a third non-concurrent control group arm in addi-
tion to the two concurrent arms [101,104,131]. The
VAP-IP of all three of these non-concurrent control
groups is less than 24% [12].
A further limitation was that the number of group
level factors that could be explored was limited by those
that were readily available and identified for all the
groups in the analysis. Origin from a European country
and year of publication were tested and found not to be
Table 5 Meta-regression models 4-6: benchmark and intervention groups
Meta-regression analysis of logit VAP-IP
Factor Coefficient
a 95% confidence interval P
Simple model (model 4; all studies)
Benchmark groups (reference group) -1.26 -1.46 to -1.06 <0.001
Non-antimicrobial series -0.32 -0.64 to -0.01 0.054
SDD series -0.37 -0.70 to -0.03 0.03
Full model (model 5; all studies)
Benchmark groups (reference group) -1.19 -1.50 to -0.89 <0.001
Non-antimicrobial series -0.46 -0.84 to -0.08 0.019
SDD series -0.54 -0.88 to -0.18 0.003
Mode of diagnosis
b -0.19 -0.50 to +0.13 0.24
Proportion trauma admissions
c +0.34 -0.07 to +0.76 0.11
<90% ventilated patients
d -0.30 -0.77 to +0.17 0.21
Full model (model 6; highest quality studies)
Benchmark groups (reference group) -1.05 -1.36 to -0.74 <0.001
Non-antimicrobial series -0.57 -0.99 to -0.16 0.008
SDD series -0.35 -1.09 to +0.39 0.34
Mode of diagnosis
b -0.30 -0.64 to +0.04 0.08
Proportion trauma admissions
c -0.06 -0.52 to +0.41 0.81
<90% ventilated patients
d -0.11 -0.60 to +0.38 0.67
SDD, Selective Digestive Decontamination; VAP-IP, Ventilator associated pneumonia incidence proportion.
a. Interpretation. The benchmark groups in each model form the reference group and the size of this coefficient equals the difference in logits from 0 (a logit
equal to 0 equates to a proportion of 50%; a logit equal to -1.26 equates to a proportion of 22.1%). The other coefficients in each model represent the additional
difference in logits for groups positive for that factor versus the reference group.
b. For diagnosis using bronchoscopic versus tracheal based sampling.
c. Per 100% of admissions being for trauma.
d. For studies for which <90% of patients received >24 hours of mechanical ventilation.
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Other factors such as the prevalence of antibiotic use
have not been explored beyond that accounted for by
duplex study design. Also the duration of mechanical
ventilation has not been considered beyond the group
average, which appeared to be similar across the strata
(Table 1). The appropriate investigation of these factors
would require patient level data to control for the possi-
ble influence of ecological bias [138].
There are three possible interpretations of these para-
doxical findings. First, publication and citation bias need
to be considered. Deriving the benchmark from four
non-systematic and one systematic reviews was done to
test the stability of the benchmark estimate (Table 2). In
replications of the benchmark range from these five
reviews separately this varies by no more than five per-
centage points.
Given that 11 of the 33 control groups from studies of
SDD are above the upper limit of the 95% prediction
range of the benchmark where only 2.5% of the distribu-
tion would be predicted to be found, this could be taken
to indicate a deficit of 407 groups below the upper limit
of the 95% prediction range of the benchmark {407 =
(11 * 97.5/2.5)- 22)}. This estimate corresponds to an
earlier test for publication bias using a funnel plot
method which indicated a deficit of >500 ‘inlier’ groups
with VAP-IP < 45% from studies of SDD that had been
unpublished or were otherwise ‘missing’ [12].
A second interpretation is that the possible impacts of
unmeasured and unknown patient level risk factors for
VAP-IP have not been evaluated in this analysis. How-
ever, for such a risk factor to account for the discrepan-
cies between the VAP-IP of the control groups of SDD
studies versus the benchmark groups is unlikely. Such
putative risk factors would need to be consistently
strong across the range of studies and yet have a pro-
foundly uneven distributionb e t w e e nt h eS D Ds t u d i e s
versus other studies. This is in contrast to the inconsis-
tent strength and direction of the known VAP risk fac-
tors [2,3].
For example, duration of mechanical ventilation is the
strongest patient level risk factor for VAP with increases
of approximately 2 per 100 patients per day of ventila-
tion during the second week of ventilation [139]. The
discrepancies in VAP-IP noted here between the control
groups of SDD studies versus the benchmark would
equate to a difference in mean duration of ventilation
across all groups of 6.8 days.
A third interpretation is a possible contextual effect of
SDD. The possibility of contextual effects due to cross
colonization and infection within the ICU environment
resulting from SDD use as was postulated in the original
study of SDD [10] needs to be considered [140]. SDD is
known to alter the colonization among recipients
[141,142]. However, identifying cross colonization within
a single study is difficult. A major limitation toward
testing this postulate is that colonization pressure [143]
and cross colonization, two crucial intermediary steps,
have not been measured in any of these studies.
Conclusions
The VAP-IP among control groups of SDD studies is
more variable and the mean is >50% greater than other
groups within the evidence base including the VAP
benchmark. These paradoxical findings cannot be
accounted for through group level adjustments for
proportion of trauma admissions, mode of VAP diagno-
sis and proportion of patients receiving prolonged
ventilation.
Apart from major publication bias, or the effect of a
major and as yet unidentified and mal-distributed
patient level VAP risk factor, or the effect of in-apparent
outbreaks [140], these paradoxical discrepancies cannot
be explained. The interpretation of the studies of SDD
treatments cannot proceed without further consideration
that SDD may have a contextual effect as originally pos-
tulated [10].
Key messages
￿ A VAP-IP benchmark derived from 45 observa-
tional (benchmark) groups of mechanically ventilated
patients is 22.1%.
￿ The mean VAP-IP of 35 control groups from stu-
dies of three non-antimicrobial methods of VAP pre-
vention versus 33 control groups of studies of SDD
are, respectively, within 2 percentage points of versus
more than 13 percentage points higher than the
benchmark.
￿ By contrast, the mean VAP-IP of 35 intervention
groups studies of non-antimicrobial methods versus
34 SDD intervention groups are each within six per-
centage points of the benchmark.
￿ The paradoxical findings are most apparent in
comparisons limited to the highest quality studies.
￿ These observations cannot readily be accounted for
with adjustments for group level factors such as pro-
portion of trauma admissions, mode of diagnosis
and study quality.
Additional material
Additional file 1: VAP-IP data for benchmark groups.
Additional file 2: VAP-IP data for component groups of studies of
non-antibiotic methods of VAP prevention.
Additional file 3: VAP-IP data for component groups of studies of
SDD.
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